SCHEMBL3559983

SCHEMBL3559983

Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)cc(C)n1

nearest known ligand 0.75

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 17/20 0.75
ADRA2A P08913 1/20 0.75
DRD2 P14416 1/20 0.75
SLC6A2 P23975 1/20 0.75
HTR2A P28223 1/20 0.75
HTR2C P28335 1/20 0.75
SLC6A4 P31645 1/20 0.75
TMEM97 Q5BJF2 1/20 0.75
SIGMAR1 Q99720 1/20 0.75
MAPT P10636 1/20 0.53
MEN1 O00255 1/20 0.49
POLB P06746 1/20 0.49
KMT2A Q03164 1/20 0.49
CHRM4 P08173 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3563302 0.93 UTS2R (0.68) UTS2RADRA2ADRD2SLC6A2HTR2A
SCHEMBL6198596 0.89 UTS2R (0.64) UTS2RADRA2ADRD2SLC6A2HTR2A
SCHEMBL5541398 0.88 UTS2R (0.70) UTS2RADRA2ADRD2SLC6A2HTR2A
Palosuran SCHEMBL1363480 0.85 UTS2R (1.00) UTS2RADRA2ADRD2SLC6A2HTR2A
Palosuran SCHEMBL29441424 0.85 UTS2R (1.00) UTS2RADRA2ADRD2SLC6A2HTR2A
SCHEMBL4828037 0.83 UTS2R (0.81) UTS2RADRA2ADRD2SLC6A2HTR2A
Palosuran SCHEMBL29441419 0.82 UTS2R (1.00) UTS2RADRA2ADRD2SLC6A2HTR2A
Palosuran SCHEMBL5265025 0.82 UTS2R (1.00) UTS2RADRA2ADRD2SLC6A2HTR2A
Palosuran SCHEMBL1364002 0.82 UTS2R (0.98) UTS2RADRA2ADRD2SLC6A2HTR2A
Palosuran SCHEMBL1363165 0.82 UTS2R (0.98) UTS2RADRA2ADRD2SLC6A2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043081-A1 Novel pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2007-02-22 US claimed
CN-1856305-A Pyridine derivatives and their use as urotensin II antagonists ACTELION PHARMACEUTICALS LTD (CH) 2006-11-01 CN claimed
US-7750161-B2 Pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2010-07-06 US disclosed
US-7750161-B2 Pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2010-07-06 US disclosed
US-7750161-B2 Pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2010-07-06 US disclosed
CN-1856305-B Pyridine derivatives as urotensin II antagonists ACTELION PHARMACEUTICALS LTD 2010-04-28 CN disclosed
US-20070043081-A1 Novel pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2007-02-22 US disclosed
US-20070043081-A1 Novel pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2007-02-22 US disclosed
US-20070043081-A1 Novel pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2007-02-22 US disclosed
CN-1856305-A Pyridine derivatives and their use as urotensin II antagonists ACTELION PHARMACEUTICALS LTD (CH) 2006-11-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043081-A1 Novel pyridine derivatives P2RY4, P2RX6, P2RX4 UTS2R 636/4885ADRA2A 30/4885DRD2 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.